KeyBanc analyst Steve Dechert initiated coverage of Zoetis (ZTS) with a Sector Weight rating. The firm is citing continued headwinds from the launch of the company’s OA pain mAb products and increased competition in key franchises, the analyst tells investors in a research note. While KeyBanc recognizes Zoetis’s history of excellence in developing innovative products, the firm sees shares as being fairly valued while it awaits new innovative product launches.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZTS: